Over-expression of fibroblast growth factor receptor 3 in human hepatocellular carcinoma.

AIM To describe the significant over-expression of fibroblast growth factor receptor 3 (FGFR3), which is a signal transduction and cell proliferation related gene in hepatocellular carcinoma (HCC). METHODS Following DNA microarray, Northern blot and quantitative real-time PCR were employed to confirm FGFR3 expression difference in HCC tissues and surrounding non-neoplastic liver tissue. FGFR3 expression levels were further determined by immunohistochemical study in 43 cases of HCC. RESULTS Northern blot results showed the significant over-expression of FGFR3 in HCC tissues, which was consistent with that from DNA microarray. Quantitative real-time PCR demonstrated that the mean ratio of FGFR3 mRNA to glyceraldehyde-3-phosphate dehydrogenase (GADPH) mRNA in HCC tissue was 0.250, whereas the ratio in non-neoplastic liver tissue was 0.014. Statistical analyses of 43 cases of HCC revealed that HCC scored higher than the matched non-neoplastic liver tissues. Examination of clinicopathological features revealed a strong correlation of over-expression of FGFR3 with poor tumor differentiation and high nuclear grade. CONCLUSION Over-expression of FGFR3 may play an important role in liver carcinogenesis. FGFR3 may be an ideal candidate as a molecular marker in the diagnosis of HCC and a potential therapeutic target.

[1]  Shaun K Olsen,et al.  Receptor Specificity of the Fibroblast Growth Factor Family , 2006, Journal of Biological Chemistry.

[2]  T. H. van der Kwast,et al.  FGFR3 and P53 Characterize Alternative Genetic Pathways in the Pathogenesis of Urothelial Cell Carcinoma , 2004, Cancer Research.

[3]  Y. Yen,et al.  Down-regulation of growth arrest DNA damage-inducible gene 45beta expression is associated with human hepatocellular carcinoma. , 2003, The American journal of pathology.

[4]  K. Batts,et al.  Prognostic Histologic Indicators of Curatively Resected Hepatocellular Carcinomas: A Multi-institutional Analysis of 425 Patients With Definition of a Histologic Prognostic Index , 2002, The American journal of surgical pathology.

[5]  Y. Eto,et al.  The incidence of thanatophoric dysplasia mutations in FGFR3 gene is higher in low‐grade or superficial bladder carcinomas , 2001, Cancer.

[6]  L. Baldini,et al.  Analysis of FGFR3 gene mutations in multiple myeloma patients with t(4;14) , 2001, British journal of haematology.

[7]  C. Abbou,et al.  Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. , 2001, The American journal of pathology.

[8]  P. Farnham,et al.  Expression profiling and identification of novel genes in hepatocellular carcinomas , 2001, Oncogene.

[9]  J. G. Park,et al.  Mutations in fibroblast growth factor receptor 2 and fibroblast growth factor receptor 3 genes associated with human gastric and colorectal cancers. , 2001, Cancer research.

[10]  T. H. van der Kwast,et al.  The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate. , 2001, Cancer research.

[11]  Holger Moch,et al.  Tissue Microarrays: What Will They Bring to Molecular and Anatomic Pathology? , 2001, Advances in anatomic pathology.

[12]  P. V. van Diest,et al.  Microarray techniques in pathology: tool or toy? , 2000, Molecular pathology : MP.

[13]  J. G. Park,et al.  Novel transcripts of fibroblast growth factor receptor 3 reveal aberrant splicing and activation of cryptic splice sequences in colorectal cancer. , 2000, Cancer research.

[14]  D. Chopin,et al.  Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas , 1999, Nature Genetics.

[15]  Jacques Ferlay,et al.  Estimates of the worldwide incidence of 25 major cancers in 1990 , 1999, International journal of cancer.

[16]  D. Donoghue,et al.  FGFR activation in skeletal disorders: too much of a good thing. , 1997, Trends in genetics : TIG.

[17]  C. MacArthur,et al.  Receptor Specificity of the Fibroblast Growth Factor Family* , 1996, The Journal of Biological Chemistry.

[18]  D. Ornitz,et al.  Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia , 1996, Nature Genetics.

[19]  F. Bertucci,et al.  Expression of fgf and fgf receptor genes in human breast cancer , 1995, International journal of cancer.

[20]  I. Mason.  The ins and outs of fibroblast growth factors , 1994, Cell.

[21]  D. Birnbaum,et al.  BEK and FLG, two receptors to members of the FGF family, are amplified in subsets of human breast cancers. , 1991, Oncogene.

[22]  H. Edmondson,et al.  Primary carcinoma of the liver. A study of 100 cases among 48,900 necropsies , 1954, Cancer.

[23]  Alicia Samuels,et al.  Cancer Statistics, 2003 , 2003, CA: a cancer journal for clinicians.

[24]  M. Kan,et al.  The heparan sulfate-fibroblast growth factor family: diversity of structure and function. , 1998, Progress in nucleic acid research and molecular biology.

[25]  D. Johnson,et al.  Structural and functional diversity in the FGF receptor multigene family. , 1993, Advances in cancer research.

[26]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.